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A B S T R A C T
Ubiquitin–proteasome system (UPS) is a primary signaling pathway for regulation of protein turnover and re-
moval of misfolded proteins in eukaryotic cells. Enzymes of the UPS pathway - E1 activating, E2 conjugating, E3
ligating - act together to covalently tag substrate proteins with a chain of ubiquitins, small regulatory proteins.
The poly-ubiquitin chain then serves as a recognition motif for 26S proteasome to recognize and degrade the
substrate. In recent years UPS has emerged as attractive enzymatic cascade for development of novel ther-
apeutics against various human diseases. Building on the previous success of targeting this pathway in cancer –
the broader scientiﬁc community is currently looking for ways to elucidate functions of E3 ligases, substrate-
speciﬁc members of the UPS. RING-type E3 ubiquitin ligases, the largest class of E3s, represent prospective
targets for small molecule modulation and their importance is reinforced by ever growing evidence of playing
role in non-cancer diseases, primarily associated with inﬂammatory and immune disorders. In this review, we
aim to brieﬂy cover the current knowledge of biological functions of RING-type E3 ligases in inﬂammation and
immunity.
1. Introduction
Intracellular signaling is primarily controlled by key post-transla-
tional modiﬁcations - phosphorylation, acetylation, and ubiquitination
[1]. Ubiquitination is carried out by the ubiquitin-proteasome system
(UPS) and is now widely recognized as the primary signaling event in
regulation of inﬂammation and immunity. In the last two decades,
scientists around the globe have witnessed increasing attention towards
UPS that regulates protein turnover in eukaryotic cells. Research in this
area substantially accelerated after the 2004 Nobel Prize in Chemistry
was awarded to Aaron Ciechanover, Avram Hershko and Irwin Rose for
their discovery of ubiquitin-mediated proteasomal protein degradation
[2]. The currently well-known molecular mechanism of the UPS ac-
tivity is regulated by consecutive action of three enzyme types (E1
activating, E2 conjugating, E3 ligating). These enzymes operate in a
concerted manner to poly-ubiquitinate a substrate protein and deﬁne its
subsequent fate (Fig. 1A) [3,4]. The chain of ubiquitin molecules, small
76 amino acid proteins, regulates molecular signaling depending on
lysine linkage type of the poly-ubiquitin moiety, its length and addi-
tional post-translational modiﬁcations. Poly-ubiquitin chain that can be
formed via seven distinct lysine residues (K6, K11, K27, K29, K33, K48,
K63). For example, K48-linked chain directs ubiquitinated substrate
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type lectin receptor; CRL, Cullin RING ligase; ERK, extracellular signalregulated kinase; FANC, Fanconi anemia ligase; FTD, frontotemporal dementia; GRAIL, gene
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NLR, NOD-like receptor; PBMC, peripheral blood mononuclear cell; PDC, plasmacytoid dendritic cell; PROTAC, proteolysis-targeting chimera; PRR, pattern re-
cognition receptor; RA, rheumatoid arthritis; RBR, RING-between RING-RING ligase; RIG-I, retinoic acid-inducible gene-I; RING, really interesting new gene; RLR,
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TNF, tumor necrosis factor; TNFRSF5, tumor necrosis factor receptor superfamily member 5; TNRF2, tumor necrosis factor receptor 2; TRAF, tumor necrosis factor
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